As we enter 2026, we believe Edgewater is exceptionally well positioned for a meaningful step-up in execution and market engagement as the industry embraces the reliability-first requirements we have ...
Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results